Archives
Anlotinib Hydrochloride: Benchmark Multi-Target Tyrosine ...
Anlotinib Hydrochloride: Benchmark Multi-Target Tyrosine Kinase Inhibitor for Anti-Angiogenic Research
Executive Summary: Anlotinib hydrochloride (APExBIO, SKU C8688) is a multi-target tyrosine kinase inhibitor (TKI) that potently inhibits VEGFR2, PDGFRβ, and FGFR1 at nanomolar IC50 values, resulting in robust suppression of angiogenesis in vitro and in vivo (Lin et al., 2018). Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates superior inhibition of endothelial cell migration and tube formation. Its pharmacokinetic profile features high membrane permeability, bioavailability, and plasma protein binding, with predominant CYP3A metabolism. Safety evaluations indicate a high LD50 and minimal off-target toxicity, supporting its use in research workflows. Anlotinib is available for research applications from APExBIO, offering reproducible results in cell-based angiogenesis assays (product page).
Biological Rationale
Angiogenesis—the process of new blood vessel formation—is essential for tumor growth, progression, and metastasis (Lin et al., 2018). Tumor cells secrete pro-angiogenic cytokines, notably VEGF, PDGF-BB, and FGF-2, to stimulate endothelial cell migration and neovascularization. The VEGFR2, PDGFRβ, and FGFR1 receptors mediate these processes, activating downstream pathways such as ERK to promote endothelial proliferation, migration, and survival. Targeting these kinases with small-molecule inhibitors is a clinically validated approach to restrict tumor vascularization and limit cancer progression (Lin et al., 2018).
Mechanism of Action of Anlotinib (hydrochloride)
Anlotinib hydrochloride is a synthetic, small-molecule TKI that targets multiple angiogenic kinases. Biochemically, it inhibits VEGFR2 (IC50: 5.6 ± 1.2 nM), PDGFRβ (IC50: 8.7 ± 3.4 nM), and FGFR1 (IC50: 11.7 ± 4.1 nM) in cell-free kinase assays (Lin et al., 2018). In endothelial cells (EA.hy 926), anlotinib blocks VEGF/PDGF-BB/FGF2-induced migration and capillary tube formation with a clear concentration-response relationship. Mechanistically, anlotinib disrupts phosphorylation of VEGFR2, PDGFRβ, and FGFR1, suppressing the ERK signaling cascade. This results in reduced microvessel density and angiogenic sprouting in ex vivo (rat aortic ring) and in vivo (CAM assay) models. The compound's multi-target activity underlies its robust anti-angiogenic efficacy.
Evidence & Benchmarks
- Anlotinib inhibits VEGFR2 kinase activity with an IC50 of 5.6 ± 1.2 nM under standardized ATP concentration (10 µM), outperforming sunitinib and sorafenib (DOI).
- PDGFRβ inhibition by anlotinib (IC50: 8.7 ± 3.4 nM) is more potent than nintedanib under comparable experimental conditions (DOI).
- FGFR1 is suppressed with an IC50 of 11.7 ± 4.1 nM, contributing to broad anti-angiogenic effects (DOI).
- Anlotinib reduces EA.hy 926 endothelial cell migration (wound healing and chamber assays) in response to VEGF/PDGF-BB/FGF-2 stimulation at 10–50 nM, with statistically significant suppression (p<0.01) (DOI).
- Capillary-like tube formation is markedly inhibited by anlotinib at 10–100 nM in Matrigel assays (DOI).
- In ex vivo aortic ring and CAM assays, anlotinib suppresses angiogenic sprouting and microvessel density at 100–500 nM (DOI).
- Pharmacokinetic studies in rats and dogs show oral bioavailability of 28–58% and 41–77%, respectively; human plasma protein binding is 93% (product page).
- Median lethal dose (LD50) in 14-day oral studies is 1735.9 mg/kg; no significant systemic or genetic toxicity detected at research concentrations (APExBIO).
- Compared to sunitinib, sorafenib, and nintedanib, anlotinib consistently achieves greater inhibition of angiogenic endpoints in matched head-to-head studies (DOI).
This article extends upon the practical guidance in "Enhancing Tumor Angiogenesis Assays with Anlotinib (hydrochloride)" by providing detailed quantitative benchmarks and mechanistic context for research-grade anlotinib hydrochloride. For advanced experimental strategies and troubleshooting, see "Anlotinib Hydrochloride: Applied Strategies for Tumor Angiogenesis", which focuses on workflow design and data reproducibility. For a broader mechanistic overview and translational outlook, consult "Anlotinib Hydrochloride: Mechanistic Depth and Strategic Outlook", which this article complements with updated IC50 and safety data.
Applications, Limits & Misconceptions
Anlotinib hydrochloride is intended for research applications in cell-based and ex vivo models of angiogenesis, signaling pathway modulation, and tumor vascularization. The compound is used in assays involving human vascular endothelial cells (EA.hy 926), migration and tube formation protocols, and evaluation of kinase signaling blockade. It is not approved for diagnostic or clinical use and should not be used as a substitute for established clinical therapies outside preclinical research settings.
Common Pitfalls or Misconceptions
- Not for clinical therapy: Anlotinib (hydrochloride) supplied by APExBIO is for scientific research use only and is not intended for diagnostic or therapeutic application (product page).
- Species differences: Pharmacokinetic and safety data may not directly translate from animal models to human systems; use caution when extrapolating concentrations or dosing.
- Target specificity: While highly selective for VEGFR2, PDGFRβ, and FGFR1, off-target effects at supra-physiological concentrations are possible—validate pathways in your model system.
- Storage and handling: Compound stability requires storage at -20°C; improper storage may degrade activity.
- Assay context: Results from endothelial cell lines may not fully recapitulate primary tissue or in vivo angiogenesis complexity.
Workflow Integration & Parameters
Anlotinib hydrochloride integrates into tumor angiogenesis and endothelial biology research as a validated tool compound for kinase pathway inhibition. For reproducible results, recommended use includes:
- Prepare stock solutions in DMSO; dilute to working concentrations (1–100 nM) in cell culture medium immediately before use.
- Apply to EA.hy 926 or primary endothelial cells in migration and tube formation assays, typically incubating for 6–24 hours at 37°C, 5% CO2.
- For ex vivo aortic ring or CAM assays, treat explants or eggs with 100–500 nM anlotinib for 48–72 hours.
- Monitor ERK pathway phosphorylation via immunoblot or ELISA as a readout for target engagement.
- Store anlotinib at -20°C, protected from light; avoid >3 freeze-thaw cycles.
For guidance on troubleshooting and maximizing assay reproducibility, consult scenario-driven best practices in "Scenario-Driven Best Practices with Anlotinib (hydrochloride)". This article adds precise IC50 and selectivity metrics to support experimental design.
Conclusion & Outlook
Anlotinib hydrochloride represents a benchmark compound for inhibition of angiogenic signaling pathways in cancer research. Its nanomolar potency, multi-target selectivity, and favorable safety profile support its adoption for mechanistic studies, target validation, and translational oncology workflows. Researchers are encouraged to obtain validated, research-grade anlotinib from APExBIO (Anlotinib (hydrochloride) product page) and to adhere to best practices for compound handling and experimental design. Ongoing research will further define its translational potential and expand its utility in angiogenesis-related disease models.